Skip to main content

Merck KGaA Value Stock - Dividend - Research Selection

Merck KGaA

ISIN: DE0006599905 , WKN: 659990

Market price date: 26.05.2020
Market price: 103,50 EUR




Merck KGaA Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 08-03-2020
Cash flow
Net operating cash flow 2.856.000.000
Capital Expenditures -943.000.000
Free cash flow 1.912.999.936
Balance sheet
Total Equity 17.865.000.000
Liabilities & Shareholders equity 43.811.000.000
Income statement
Net income 1.320.000.000
Eps (diluted) 3,040
Diluted shares outstanding 434.211.000
Net sales/revenue 16.152.000.000

Fundamental ratios calculated on: 26-05-2020

Ratios
Key figures 26-05-2020
Cash flow
P/C 15,74
   
P/FC 23,49
Balance sheet
ROI3,01
ROE40,78
Income statement
P/E34,05
Div. Yield1,26%
P/B2,52
P/S2,78


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolMRK.DE
Market Capitalization50.332.663.808,00 USD
CountryGermany
IndicesDax,HDAX
SectorsPharma
Raw Data SourceIFRS in Millionen EUR
Stock Split2014-06-30,2.0000/1.0000; 2007-01-24,1367.000000/1346.000000
Internetwww.merckgroup.com


Description of the company

MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments. It also provides over-the counter and food supplement products under the Neurobion, Bion3, Seven Seas, Nasivin, Femibion, Dolo-Neurobion, Vivera/Floratil, Sangobion, Vigantoletten, Apaisyl, and Kytta brands. In addition, the company offers life science products and services for use in the discovery, development, and manufacture of biotechnological drugs, as well as in research and application laboratories; and specialty chemicals and functional materials for applications consumer electronics, lighting, coatings, printing technology, paints, plastics, and cosmetics. It has strategic alliances with Pfizer Inc. and Baylor College of Medicine; an agreement with Bristol-Myers Squibb Company for the co-commercialization of Glucophage, an antidiabetic agent in China; a strategic collaboration and license agreement with Intrexon Corporation to develop and commercialize chimeric antigen receptor T-cell cancer therapies; and collaborations with F-star Delta Ltd. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.merckgroup.com